Vifor Pharma

Iron deficiency / nephrology therapeutics (part of CSL group since 2022)

Subsidiary of CSL Limited (CSL) · Switzerland

Assets

(7 total)
7Total Assets
5Approved
1Phase 3 / Filed
1Phase 1–2 / Early
6Diseases
Quick filter:
Showing 7 of 7 assets
Target & Modality
Difelikefalin(Korsuva)
Approved
Kappa-opioid receptor (agonist, peripherally restricted)Peptide
Chronic Kidney Disease
Approved
Vitamin D receptor (VDR), via conversion to calcitriolSmall molecule
Chronic Kidney Disease
Secondary Hyperparathyroidism
Ferric carboxymaltose(Injectafer / Ferinject)
Approved
Iron repletionOther
Heart FailureChronic Kidney DiseaseIron Deficiency Anemia
sparsentan(Filspari)
Approved
Angiotensin II receptor type 1 (AT1R) + Endothelin receptor type A (ETA)Small molecule
Focal Segmental GlomerulosclerosisIgA Nephropathy
Approved
Dietary phosphateSmall molecule
Chronic Kidney DiseaseHyperphosphatemia
Patiromer(Veltassa)
Phase 3
Gastrointestinal potassium binderSmall molecule
Chronic Kidney Disease
Avacopan(Tavneos)
Phase 2
Complement C5a receptor 1 (C5aR1/CD88)Small molecule
Chronic Kidney Disease

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (3)
March 2027 (1)
sparsentan · FilspariPhase 2Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis, Alport Syndrome
Est. primary completion 2027-03-12 · NCT05003986 · CT.gov ↗
What to watch
July 2027 (1)
Avacopan · TavneosPhase 3Vasculitis
Est. primary completion 2027-07-18 · NCT06321601 · CT.gov ↗
What to watch
October 2027 (1)
Extended-release calcifediol · RayaldeePhase 2CKD Stage 3, CKD Stage 4, Secondary Hyperparathyroidism, VDI
Est. primary completion 2027-10 · NCT07494045 · CT.gov ↗
What to watch
2029 (2)
August 2029 (1)
Difelikefalin · KorsuvaPhase 2Pruritus, Chronic Kidney Diseases
Est. primary completion 2029-08-15 · NCT06593392 · CT.gov ↗
What to watch
December 2029 (1)
Patiromer · VeltassaPhase 2Hyperkalemia
Est. primary completion 2029-12-01 · NCT05766839 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(4)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

4 August 2026WithdrawalAvacopanEuropean Commission revokes the EU marketing authorisation of Tavneos (Article 20 review of ADVOCATE data handling)
EU, EMA/EC · European Commission · Source ↗
30 April 2026Withdrawal proposedAvacopanFDA proposes to withdraw approval of TAVNEOS (NDA held by ChemoCentryx, an Amgen company); opportunity for a hearing
US, FDA · FDA (CDER) · Source ↗
14 April 2026ApprovalsparsentanFDA approves FILSPARI for FSGS
US, FDA · Source ↗
5 September 2024ApprovalsparsentanFDA grants full approval of Filspari in IgA nephropathy
US, FDA · Source ↗

Financial reports

No financial reports recorded.